About grass allergy
Grass allergy, commonly referred to as hay fever, is extremely prevalent. In Europe and the United States grasses are the most common cause of seasonal allergy, with approximately 15 - 25% of the population sensitised to pollen from different species. Grass allergy can debilitate sufferers during the months when pollen is released, resulting in poor concentration, reduced performance and workplace and school absences.
About ToleroMune® technology
Circassia is developing a range of allergy treatments based on its novel, proprietary ToleroMune® technology. This uses rationally-designed molecules identified from common allergens (Synthetic Peptide Immuno-Regulatory Epitopes; SPIREs) to generate regulatory T cells to control allergic responses and induce immune tolerance. Circassia has achieved successful phase II results with its cat, house dust mite, ragweed and grass allergy therapies, and its cat allergy treatment entered phase III testing in October 2012.
Clinical results show that short, simple courses of SPIRE allergy treatments can greatly reduce patients' allergic responses and improve symptoms over long periods, while proving extremely well tolerated. As a result, SPIRE treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities. More than 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is valued at approximately $12 billion per year.
|SOURCE Circassia Ltd|
Copyright©2012 PR Newswire.
All rights reserved